Baptiste Chevet

Baptiste Chevet

Auto-generated profile, based on publicly available information

Baptiste Chevet

Rheumatology department, Brest University Hospital, Brest, France; LBAI, UMR1227, Univ Brest, Inserm, Brest, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Rheumatology
Verified
Journal Article
Closed access
PDF file
MAMorgane Assaraf
Morgane Assaraf
BCBaptiste Chevet
Baptiste Chevet
DWDaniel Wendling
Daniel Wendling
PPPeggy Philippe
Peggy Philippe
ECEmeline Cailliau
Emeline Cailliau
VDValérie Devauchelle-Pensec
Valérie Devauchelle-Pensec
Objectives: The efficacy of anti-IL-6 receptors such as tocilizumab (TCZ) was demonstrated in patients with PMR in two recent randomized controlled trials. The objective of this multicentre retrospective study was to assess the efficacy of TCZ in PMR patients requiring glucocorticoid (GC)-sparing treatment, as well as different strategies for TCZ withdrawal. Methods: We conducted a multicentre study in French tertiary healthcare departments for patients with PMR. PMR patients receiving off-label TCZ between 2015 and 2022 were included. The primary endpoint was the proportion of patients tapering to GCs ≤5 mg/day 6 months after the first TCZ infusion. The secondary endpoints were the proportion in whom GC was discontinued during follow-up, and the proportion of patients in whom TCZ was discontinued. Results: Fifty-three PMR patients were included. Thirty-one patients suffered from active PMR despite conventional synthetic DMARDs. GCs were ≤5 mg/day in 77% of the patients (95% CI 36–89) at 6 months, and in 97% of the patients at 12 months. Six and 12 months after the first TCZ infusion, the proportions of GC-free patients were 22.5% (95% CI 12.7–37.8) and 58.3% (95% CI 43.2–74.1), respectively. Among TCZ withdrawal strategies, TCZ infusion spacing and TCZ dose reduction were more successful (success in 87% and 79% of attempts, respectively) than TCZ discontinuation (success in 52% of attempts; P = 0.012 and P = 0.039, respectively). Conclusion: In GC-dependent PMR patients, treatment with TCZ led to a drastic decrease in GC dose and remission of PMR. TCZ dose reduction or TCZ infusion spacing are good options to consider in TCZ withdrawal.

15 November 2022 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
GFGabriel Figueroa-Parra
Gabriel Figueroa-Parra
MJMolly M. Jeffery
Molly M. Jeffery
JDJesse Y. Dabit
Jesse Y. Dabit
BCBaptiste Chevet
Baptiste Chevet
MVMaria O. Valenzuela-Almada
Maria O. Valenzuela-Almada
ADAlí Duarte-García
Alí Duarte-García
Objective: There is little information about the epidemiology and factors associated with opioid therapy in systemic lupus erythematosus (SLE). We aimed to assess the prevalence of opioid therapy and explore factors associated with long-term opioid therapy (LTOT) in patients with SLE.Methods: Patients with SLE were matched with controls without SLE in a population-based cohort on January 1, 2015. We captured demographics, manifestations of SLE, comorbidities (ie, fibromyalgia, mood disorders, osteoarthritis, chronic low back pain [CLBP], chronic kidney disease (CKD), avascular necrosis, osteoporosis, fragility fractures, and cancer), and the Area Deprivation Index (ADI). Opioid prescription data were used to assess the prevalence of LTOT, defined as contiguous prescriptions (gaps of < 30 days between prescriptions) and receiving opioid therapy for ≥ 90 days or ≥ 10 prescriptions before the index date.Results: A total of 465 patients with SLE and 465 controls without SLE were included. In total, 13% of patients with SLE and 3% of controls without SLE were receiving opioid therapy (P< 0.001), and 11% of patients with SLE were on LTOT vs 1% of controls without SLE. Among patients with SLE, acute pericarditis (odds ratio [OR] 3.92, 95% CI 1.78-8.66), fibromyalgia (OR 7.78, 95% CI 3.89-15.55), fragility fractures (OR 3.72, 95% CI 1.25-11.07), CLBP (OR 4.00, 95% CI 2.13-7.51), and mood disorders (OR 2.76, 95% CI 1.47-5.16) were associated with LTOT. We did not find an association between opioid therapy and ADI.Conclusion: Patients with SLE are more likely to receive LTOT than controls. Among patients with SLE, LTOT was associated with pericarditis and several comorbidities. However, LTOT was not associated with CKD despite the limited pain control options among these patients.

1 September 2022 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
BCBaptiste Chevet
Baptiste Chevet
GFGabriel Figueroa-Parra
Gabriel Figueroa-Parra
JYJeffrey X. Yang
Jeffrey X. Yang
MHMehmet Hocaoglu
Mehmet Hocaoglu
SOShirley-Ann Osei-Onomah
Shirley-Ann Osei-Onomah
ADAlí Duarte-García
Alí Duarte-García
Background: Systemic lupus erythematosus (SLE) is a disease that can lead to damage of multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular disease, diabetes, osteoporosis, and infections. Preventive services are particularly important in patients with SLE to mitigate the aforementioned risks. We aimed to evaluate the trends of preventive services utilization in patients with systemic lupus erythematosus, compared with non-SLE population. Methods: All ≥19-year-old patients in the Lupus Midwest Network (LUMEN) registry, a population-based cohort, with SLE on January 1, 2015, were included and matched (1:1) by sex, age, race, and county to non-SLE comparators. Among both groups, we compared the rates of screenings for breast and cervical cancer, hypertension, hyperlipidemia, diabetes mellitus, and osteoporosis as well as immunizations. Results: We included 440 SLE patients and 430 non-SLE comparators. The probability of breast cancer screening among women with SLE was similar to comparators (hazard ratio [HR] 1.09, 95% CI 0.85–1.39), while cervical cancer screening was lower (HR 0.75, 95% CI 0.58–0.96). Hypertension screening was higher among patients with SLE (HR 1.35, 95% CI 1.13–1.62); however, hyperlipidemia screening was similar to comparators (HR 1.16, 95% CI 0.96–1.41). Diabetes and osteoporosis screenings were more likely to be performed for SLE patients than for comparators (HR 2.46, 95% CI 2.11–2.87; and HR 3.19, 95% CI 2.31–4.41; respectively). Influenza and pneumococcal immunizations were higher among SLE patients (HR 1.31, 95% CI 1.12–1.54; and HR 2.06, 95% CI 1.38–3.09; respectively), while zoster vaccination was similar (HR 1.17, 95% CI 0.81–1.69). Conclusions: The trends of utilization of preventive services by SLE patients vary according to screening or vaccine compared with the general population. Considering these differences, we demonstrate an opportunity for improvement, particularly in cervical cancer, hyperlipidemia, and osteoporosis screenings and vaccinations.

20 November 2024 in Joint Bone Spine
Verified
Journal Article
Closed access
BCBaptiste Chevet
Baptiste Chevet
DCDivi Cornec
Divi Cornec

7 May 2025 in Arthritis & Rheumatology
Verified
Journal Article
Open access
BCBaptiste Chevet
Baptiste Chevet
ASAghiles Souki
Aghiles Souki
ENEmmanuel Nowak
Emmanuel Nowak
GCGuillermo Carvajal‐Alegria
Guillermo Carvajal‐Alegria
EDEmmanuelle Dernis
Emmanuelle Dernis
VDValérie Devauchelle‐Pensec
Valérie Devauchelle‐Pensec
Objective: The SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) in glucocorticoid (GC)‐dependent polymyalgia rheumatica (PMR). TCZ reduced GC use and disease activity at 24 weeks.This study aimed to assess relapse rates after stopping TCZ in patients achieving remission at week 24.Methods: In the randomized study, 101 patients received intravenous TCZ (8 mg/kg) or placebo for 24 weeks. Of the 49 TCZ‐treated patients, 33 achieved the primary outcome (PMR‐activity score <10 and GC reduction of ≤5 mg/day or ≥10 mg).All 33 patients except one stopped TCZ at week 24, completed a visit at week 32, with optional follow‐up visits every 8 weeks until week 48. Relapse was defined as the failure of the primary composite outcome during follow‐up or the need for ≥1 TCZ infusion. Results were analyzed using Kaplan–Meier curves.Results: Among the 33 patients who received TCZ in remission at week 24, seven stopped follow‐up before the 48th week, and two of the remaining 26 subjects (7.7%) sustained remission in the following 6 months. 24 (92.3%) of the total patients experienced relapse. The median time to relapse was 15 weeks (interquartile range: 8–25).Conclusion: Among patients with GC‐dependent PMR, in remission after a 6‐month TCZ treatment, only a minority of the patients remained relapse‐free after TCZ discontinuation. This study suggests that a 6‐month treatment course is not a long enough to withdraw the TCZ. Further studies are needed to determine the optimal TCZ treatment duration and strategies for cessation to prevent relapses.

29 March 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
EBEléonore Bettacchioli
Eléonore Bettacchioli
JFJean-Baptiste Foulquier
Jean-Baptiste Foulquier
BCBaptiste Chevet
Baptiste Chevet
EGEmilie Cornec-Le Gall
Emilie Cornec-Le Gall
CHCatherine Hanrotel
Catherine Hanrotel
DCDivi Cornec
Divi Cornec
Objectives: Anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV) are rare conditions characterized by inflammatory cell infiltration in small blood vessels, leading to tissue necrosis. While most patients with AAV present antibodies against either myeloperoxidase (MPO) or proteinase 3 (PR3), rare cases of dual positivity for both antibodies (DP-ANCA) have been reported, and their impact on the clinical picture remains unclear. The goal of this study was to investigate the clinical implications, phenotypic profiles and outcomes of patients with DP-ANCA. Methods: A retrospective screening for DP-ANCA cases was conducted at Brest University Hospital's immunology laboratory (France), analysing ANCA results from March 2013 to March 2022. Clinical, biological, imaging, and histological data were collected for each DP-ANCA case. Additionally, a comprehensive literature review on DP-ANCA was performed, combining an artificial intelligence (AI)-based search using BIBOT software with a manual PUBMED database search. Results: The report of our cases over the last 9 years and those from the literature yielded 103 described cases of patients with DP-ANCA. We identified four distinct phenotypic profiles: (i) idiopathic AAV (∼30%); (ii) drug-induced AAV (∼25%); (iii) autoimmune disease associated with a low risk of developing vasculitis (∼20%); and (iv) immune-disrupting comorbidities (infections, cancers, etc) not associated with AAV (∼25%). Conclusion: This analysis of over a hundred DP-ANCA cases suggests substantial diversity in clinical and immunopathological presentations. Approximatively 50% of DP-ANCA patients develop AAV, either as drug-induced or idiopathic forms, while the remaining 50%, characterized by pre-existing dysimmune conditions, demonstrates a remarkably low vasculitis risk. These findings underscore the complex nature of DP-ANCA, its variable impact on patient health, and the necessity for personalized diagnostic and management approaches in these cases.